SCHEMBL9629185

SCHEMBL9629185

O=C1c2cccnc2N(c2cccc(Cl)c2)C(=O)C12CCCCO2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 1/20 0.36
KDM4E B2RXH2 3/20 0.36
ALDH1A1 P00352 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
MEN1 O00255 4/20 0.35
KMT2A Q03164 4/20 0.35
CASP6 P55212 1/20 0.35
MAPT P10636 4/20 0.34
MGLL Q99685 1/20 0.34
CYP1A2 P05177 1/20 0.34
HPGD P15428 1/20 0.34
CYP2C19 P33261 1/20 0.34
ADCY2 Q08462 1/20 0.33
LMNA P02545 1/20 0.33
PKM P14618 1/20 0.33
ALOX15 P16050 1/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
HSD17B10 Q99714 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9537511 0.89 PGR (0.41) PGRALDH1A1MEN1KMT2AMAPT
SCHEMBL9629039 0.88 EGLN1 (0.34) PGRKDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL9628950 0.87 MAPT (0.38) KDM4EALDH1A1MEN1KMT2AMAPT
SCHEMBL9629835 0.85 EGLN1 (0.34) PGRKDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL9352368 0.82 PGR (0.42) PGRKDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL9628874 0.81 EGLN1 (0.36) PGRKDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL9533735 0.75 LMNA (0.36) KDM4EALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL9536299 0.71 MAPT (0.39) KDM4EALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL9348228 0.71 PGR (0.55) PGRMEN1KMT2AMAPTHPGD
SCHEMBL9348203 0.70 NPC1 (0.40) PGRKDM4EALDH1A1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0338010-B1 PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF HYPERPROLIFERATE SKIN DISEASE SCHERING CORPORATION (US) 1992-02-05 EP claimed
EP-0228416-B1 PHARMACEUTICAL COMPOSITIONS CONTAINING AZANAPHTHALENES SCHERING CORPORATION (US) 1990-03-21 EP claimed
EP-0144996-B1 SUBSTITUTED SPIRO PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THE PREPARATION OF SUCH COMPOUNDS AND COMPOSITIONS SCHERING CORPORATION (US) 1990-02-28 EP claimed
EP-0338010-A1 PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF HYPERPROLIFERATE SKIN DISEASE. SCHERING CORP (US) 1989-10-25 EP claimed
WO-1988004172-A1 PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF HYPERPROLIFERATE SKIN DISEASE SCHERING CORPORATION (US) 1988-06-16 WO claimed
EP-0228416-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING AZANAPHTHALENES. SCHERING CORP (US) 1987-07-15 EP claimed
WO-1986007537-A2 PHARMACEUTICAL COMPOSITIONS CONTAINING AZANAPHTHALENES SCHERING CORPORATION (US) 1986-12-31 WO claimed
EP-0144996-A2 Substituted spiro pyridine derivatives, pharmaceutical compositions containing them and processes for the preparation of such compounds and compositions SCHERING CORPORATION (US) 1985-06-19 EP claimed
EP-0144996-B1 SUBSTITUTED SPIRO PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THE PREPARATION OF SUCH COMPOUNDS AND COMPOSITIONS SCHERING CORPORATION (US) 1990-02-28 EP disclosed
US-4775524-A PSORIASIS SCHERING CORPORATION (US) 1988-10-04 US disclosed
US-4632923-A Substituted hetero spiro pyridine derivatives as anti-allergy and anti-inflammatory agents SCHERING CORPORATION (US) 1986-12-30 US disclosed